Cargando…

Positive & Negative Roles of Innate Effector Cells in Controlling Cancer Progression

Innate immune cells are active at the front line of host defense against pathogens and now appear to play a range of roles under non-infectious conditions as well, most notably in cancer. Establishing the balance of innate immune responses is critical for the “flavor” of these responses and subseque...

Descripción completa

Detalles Bibliográficos
Autores principales: Stolk, Dorian, van der Vliet, Hans J., de Gruijl, Tanja D., van Kooyk, Yvette, Exley, Mark A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6161645/
https://www.ncbi.nlm.nih.gov/pubmed/30298063
http://dx.doi.org/10.3389/fimmu.2018.01990
_version_ 1783359029181939712
author Stolk, Dorian
van der Vliet, Hans J.
de Gruijl, Tanja D.
van Kooyk, Yvette
Exley, Mark A.
author_facet Stolk, Dorian
van der Vliet, Hans J.
de Gruijl, Tanja D.
van Kooyk, Yvette
Exley, Mark A.
author_sort Stolk, Dorian
collection PubMed
description Innate immune cells are active at the front line of host defense against pathogens and now appear to play a range of roles under non-infectious conditions as well, most notably in cancer. Establishing the balance of innate immune responses is critical for the “flavor” of these responses and subsequent adaptive immunity and can be either “good or bad” in controlling cancer progression. The importance of innate NK cells in tumor immune responses has already been extensively studied over the last few decades, but more recently several relatively mono- or oligo-clonal [i.e., (semi-) invariant] innate T cell subsets received substantial interest in tumor immunology including invariant natural killer T (iNKT), γδ-T and mucosal associated invariant T (MAIT) cells. These subsets produce high levels of various pro- and/or anti-inflammatory cytokines/chemokines reflecting their capacity to suppress or stimulate immune responses. Survival of patients with cancer has been linked to the frequencies and activation status of NK, iNKT, and γδ-T cells. It has become clear that NK, iNKT, γδ-T as well as MAIT cells all have physiological roles in anti-tumor responses, which emphasize their possible relevance for tumor immunotherapy. A variety of clinical trials has focused on manipulating NK, iNKT, and γδ-T cell functions as a cancer immunotherapeutic approach demonstrating their safety and potential for achieving beneficial therapeutic effects, while the exploration of MAIT cell related therapies is still in its infancy. Current issues limiting the full therapeutic potential of these innate cell subsets appear to be related to defects and suppressive properties of these subsets that, with the right stimulus, might be reversed. In general, how innate lymphocytes are activated appears to control their subsequent abilities and consequent impact on adaptive immunity. Controlling these potent regulators and mediators of the immune system should enable their protective roles to dominate and their deleterious potential (in the specific context of cancer) to be mitigated.
format Online
Article
Text
id pubmed-6161645
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-61616452018-10-08 Positive & Negative Roles of Innate Effector Cells in Controlling Cancer Progression Stolk, Dorian van der Vliet, Hans J. de Gruijl, Tanja D. van Kooyk, Yvette Exley, Mark A. Front Immunol Immunology Innate immune cells are active at the front line of host defense against pathogens and now appear to play a range of roles under non-infectious conditions as well, most notably in cancer. Establishing the balance of innate immune responses is critical for the “flavor” of these responses and subsequent adaptive immunity and can be either “good or bad” in controlling cancer progression. The importance of innate NK cells in tumor immune responses has already been extensively studied over the last few decades, but more recently several relatively mono- or oligo-clonal [i.e., (semi-) invariant] innate T cell subsets received substantial interest in tumor immunology including invariant natural killer T (iNKT), γδ-T and mucosal associated invariant T (MAIT) cells. These subsets produce high levels of various pro- and/or anti-inflammatory cytokines/chemokines reflecting their capacity to suppress or stimulate immune responses. Survival of patients with cancer has been linked to the frequencies and activation status of NK, iNKT, and γδ-T cells. It has become clear that NK, iNKT, γδ-T as well as MAIT cells all have physiological roles in anti-tumor responses, which emphasize their possible relevance for tumor immunotherapy. A variety of clinical trials has focused on manipulating NK, iNKT, and γδ-T cell functions as a cancer immunotherapeutic approach demonstrating their safety and potential for achieving beneficial therapeutic effects, while the exploration of MAIT cell related therapies is still in its infancy. Current issues limiting the full therapeutic potential of these innate cell subsets appear to be related to defects and suppressive properties of these subsets that, with the right stimulus, might be reversed. In general, how innate lymphocytes are activated appears to control their subsequent abilities and consequent impact on adaptive immunity. Controlling these potent regulators and mediators of the immune system should enable their protective roles to dominate and their deleterious potential (in the specific context of cancer) to be mitigated. Frontiers Media S.A. 2018-09-21 /pmc/articles/PMC6161645/ /pubmed/30298063 http://dx.doi.org/10.3389/fimmu.2018.01990 Text en Copyright © 2018 Stolk, van der Vliet, de Gruijl, van Kooyk and Exley. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Stolk, Dorian
van der Vliet, Hans J.
de Gruijl, Tanja D.
van Kooyk, Yvette
Exley, Mark A.
Positive & Negative Roles of Innate Effector Cells in Controlling Cancer Progression
title Positive & Negative Roles of Innate Effector Cells in Controlling Cancer Progression
title_full Positive & Negative Roles of Innate Effector Cells in Controlling Cancer Progression
title_fullStr Positive & Negative Roles of Innate Effector Cells in Controlling Cancer Progression
title_full_unstemmed Positive & Negative Roles of Innate Effector Cells in Controlling Cancer Progression
title_short Positive & Negative Roles of Innate Effector Cells in Controlling Cancer Progression
title_sort positive & negative roles of innate effector cells in controlling cancer progression
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6161645/
https://www.ncbi.nlm.nih.gov/pubmed/30298063
http://dx.doi.org/10.3389/fimmu.2018.01990
work_keys_str_mv AT stolkdorian positivenegativerolesofinnateeffectorcellsincontrollingcancerprogression
AT vandervliethansj positivenegativerolesofinnateeffectorcellsincontrollingcancerprogression
AT degruijltanjad positivenegativerolesofinnateeffectorcellsincontrollingcancerprogression
AT vankooykyvette positivenegativerolesofinnateeffectorcellsincontrollingcancerprogression
AT exleymarka positivenegativerolesofinnateeffectorcellsincontrollingcancerprogression